137 results
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
:
In millions
Estimated Use of
Proceeds
Actual Use of
Proceeds
Variance
Nash Phase 3 clinical trial
Oncology R&D
Commercial and marketing activities …
Montreal, Québec H3A 1T8
R&D Expenses
R&D expenses in the three-month period ended February 29, 2024 amounted to $3,752,000 compared to $9,356,000
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
revenues and the management of its expenses (including the reorganization mainly focused on its R&D activities in order to meet or exceed the Marathon
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Apr 24
Theratechnologies Reports Financial Results
8:16am
in 2024, cost of goods sold was relatively stable for Trogarzo, but was affected for EGRIFTA SV® by slightly higher production related costs.
R&D Expenses …
R&D expenses in the three-month period ended February 29, 2024 amounted to $3,752,000 compared to $9,356,000 in the comparable period of Fiscal
6-K
EX-99.1
THTX
Theratechnologies Inc.
22 Mar 24
Theratechnologies Announces Update on its Preclinical Oncology Research Program
4:27pm
as it seeks partners to advance R&D
MONTREAL, March 22, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX … this wealth of data and insights to attract an oncology R&D partner.”
The Company will continue to share accumulated preclinical data, including
6-K
EX-99.1
bu7tc75e8g0i g05cj
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
EX-99.1
50g9n ga6oa2q
24 Oct 23
Material Change Report
2:46pm
6-K
EX-99.1
x46cnwzmc7yemdhgj
24 Oct 23
Theratechnologies Announces Operational Update
8:24am
6-K
EX-99.1
lcz3nrw0ge2fopp60pr
26 Sep 23
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
8:02am
6-K
EX-99.1
rim29fxfxvytkyw
26 Sep 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.2
vzphvhzza5
26 Sep 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.2
w0cfcofr95r10
12 Jul 23
Interim Consolidated Financial Statements
8:02am
6-K
EX-99.1
qhegx7
12 Jul 23
Interim Consolidated Financial Statements
8:02am
6-K
EX-99.1
qy7sza1hz8p816 52
12 Jul 23
Theratechnologies Reports Second Quarter 2023
8:00am
6-K
EX-99.2
irp2oos2yttg4b zo
12 Apr 23
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.1
2jl5c76e
12 Apr 23
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
7:45am
6-K
EX-99.2
4tdnmgy 0kjmq0pelt1
13 Oct 22
Interim Consolidated Financial Statements
8:01am
6-K
EX-99.1
ezobd1hku0f k59
13 Oct 22
Theratechnologies Reports Financial Results
7:45am
6-K
EX-99.2
aet9vwbgc6tb8m
14 Jul 22
Interim Consolidated Financial Statements
8:00am
6-K
EX-99.1
0fd7qir
14 Jul 22
Theratechnologies Reports Second Quarter and First Half
7:45am